β3 integrin subunit mediates the bone-resorbing function exerted by cultured myeloma plasma cells

Cancer Research

Volumn 69, Issue 16, 2009, Pages 6738-6746

  Tucci, Marco ^a   De Palma, Raffaele ^b   Lombardi, Lucia ^a   Rodolico, Gabriella ^b   Berrino, Liberato ^b   Dammacco, Franco ^a   Silvestris, Franco ^a  

^a UNIVERSITY OF BARI   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA3 INTEGRIN; MITOGEN ACTIVATED PROTEIN KINASE; NUCLEAR FACTOR;

ARTICLE; BONE CANCER; BONE DISEASE; BONE EROSION; CANCER CELL; CELL FUNCTION; CLINICAL ARTICLE; CLINICAL ASSESSMENT; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; MICROARRAY ANALYSIS; MULTIPLE MYELOMA; MYELOMA CELL; OSTEOCLAST; OSTEOLYSIS; PHENOTYPE; PLASMA CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; T LYMPHOCYTE; UPREGULATION;

BONE RESORPTION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; INTEGRIN ALPHA5; INTEGRIN BETA3; MACROPHAGE COLONY-STIMULATING FACTOR; MULTIPLE MYELOMA; OSTEOCLASTS; OSTEOPONTIN; PROTEIN SUBUNITS; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED;

EID: 69249134137     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-0949     Document Type: Article

References (39)

1. Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell 2002;110:673-87.
2. 3 integrins in osteoclast function. J Bone Miner Metab 2007;25:337-44.
3. Wagner EF, Matsuo K. Signalling in osteoclasts and the role of Fos/AP1 proteins. Ann Rheum Dis 2003;62 Suppl 2:83-5.
4. Takayanagi H. The role of NFAT in osteoclast formation. Ann N Y Acad Sci 2007;1116:227-37.
5. Asagiri M, Takayanagi H. The molecular understanding of osteoclast differentiation. Bone 2007;40: 251-64.
6. Mahabeleshwar GH, Feng W, Phillips DR, Byzova TV. Integrin signaling is critical for pathological angiogenesis. J Exp Med 2006;203:2495-507.
7. 3 gene therapy suppresses subcutaneously implanted epatocellular carcinomas. Dig Liver Dis 2007;39:557-65.
8. 3 integrin, and ITAM immunoreceptors, in concert, reglate osteoclastic bone resorption. J Cell Biol 2007;176: 877-88.
9. 3 integrins are osteosclerotic because of dysfunctional osteoclasts. J Clin Invest 2000;105:433-40.
10. Ria R, Vacca A, Ribatti D, Di Raimondo F, Merchionne F, Dammacco F. α(v)β(3) integrin engagement enhances cell invasiveness in human multiple myeloma. Haematologica 2002;87:836-45.
11. Abe M, Hiura K, Wilde J, et al. Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion. Blood 2004;104:2484-91.
12. Calvani N, Silvestris F, Cafforio P, Dammacco F. Osteoclast-like cell formation by circulating myeloma B lymphocytes: role of RANK-L. Leuk Lymphoma 2004;45: 377-80.
13. Calvani N, Cafforio P, Silvestris F, Dammacco F. Functional osteoclast-like transformation of cultured human myeloma cell lines. Br J Haematol 2005;130: 926-38.
14. Silvestris F, Cafforio P, De Matteo M, Quatraro C, Dammacco F. Expression and function of the calcitonin receptor by myeloma cells in their osteoclast-like activity in vitro. Leuk Res 2008;32:611-23.
15. Zhang Z, Neff L, Bothwell AL, Baron R, Horne WC. Calcitonin induces dephosphorylation of Pyk2 and phosphorylation of focal adhesion kinase in osteoclasts. Bone 2002;31:359-65.
16. Andersen TL, Boissy P, Sondergaard TE, et al. Osteoclast nuclei of myeloma patients show chromosome translocations specific for the myeloma cell clone: a new type of cancer-host partnership? J Pathol 2007;211:10-7.
17. Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol 2005;23:3412-20.
18. Silvestris F, Cafforio P, Calvani N, De Matteo M, Lombardi L, Dammacco F. In-vitro functional phenotypes of plasma cell lines from patients with multiple myeloma. Leuk Lymphoma 2006;47:1921-31.
19. Trainor KJ, Brisco MJ, Story CJ, Morley AA. Monoclonality in B-lymphoproliferative disorders detected at the DNA level. Blood 1990;75:2220-2.
20. Borson ND, Lacy MQ, Wettstein PJ. Altered mRNA expression of Pax5 and Blimp-1 in B cells in multiple myeloma. Blood 2002;100:4629-39.
21. Mahmoud MS, Huang N, Nobuyoshi M, Lisukov IA, Tanaka H, Kawano MM. Altered expression of Pax-5 gene in human myeloma cells. Blood 1996;87:4311-5.
22. Erickson KD, Martin JM. Early detection of the lytic LMP-1 protein in EBV-infected B-cells suggests its presence in the virion. Virology 1997;234:1-13.
23. Faust J, Lacey DL, Hunt P, et al. Osteoclast markers accumulate on cells developing fromhuman peripheral blood mononuclear precursors. J Cell Biochem 1999;72:67-80.
24. Grano M, Colucci S, De Bellis M, et al. New model for bone resorption study in vitro: human osteoclast-like cells from giant cell tumors of bone. J Bone Miner Res 1994;9:1013-20.
25. 3 integrin conformations in resting and resorbing osteoclasts. J Cell Sci 2002; 115:2919-29.
26. Parmo-Cabanas M, Molina-Ortiz I, Matias-Roman S, et al. Role of metalloproteinases MMP-9 and MT1-MMP in CXCL12-promoted myeloma cell invasion across basement membranes. J Pathol 2006;208:108-18.
27. 3 integrin. J Cell Biol 2003;162:499-509.
28. 3 integrin specifically impairs osteoclast function. J Clin Invest 2001;107:1137-44.
29. Soriano P, Montgomery C, Geske R, Bradley A. Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell 1991;64:693-702.
30. -/- osteoclast phenotype. J Cell Biochem 2003;90:871-83.
31. Muller DW, Bosserhoff AK. Integrin β(3) expression is regulated by let-7a miRNA in malignant melanoma. Oncogene 2008;27:6698-706.
32. 3 expression by bone-residing breast cancer metastases. Diagn Mol Pathol 1996;5:127-35.
33. Kang Y, Siegel PM, Shu W, et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003;3:537-49.
34. Minn AJ, Kang Y, Serganova I, et al. Distinct organspecific metastatic potential of individual breast cancer cells and primary tumors. J Clin Invest 2005;115:44-55.
35. Breitkreutz I, Raab MS, Vallet S, et al. Targeting MEK1/2 blocks osteoclast differentiation, function and cytokine secretion in multiple myeloma. Br J Haematol 2007;139:55-63.
36. Novack DV, Teitelbaum SL. The osteoclast: friend or foe? Annu Rev Pathol 2008;3:457-84.
37. Shaughnessy J, Jr., Zhan F, Barlogie B, Stewart AK. Gene expression profiling and multiple myeloma. Best Pract Res Clin Haematol 2005;18:537-52.
38. Haaber J, Abildgaard N, Knudsen LM, et al. Myeloma cell expression of 10 candidate genes for osteolytic bone disease. Only overexpression of DKK1 correlates with clinical bone involvement at diagnosis. Br J Haematol 2008;140:25-35.
39. Vanderkerken K, Asosingh K, Croucher P, Van Camp B. Multiple myeloma biology: lessons from the 5TMM models. Immunol Rev 2003;194:196-206.